NCT02562859View on ClinicalTrials.gov

Oral Bioavailability of Solid Formulation of GLPG1837 With and Without Food

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
Healthy
Interventions
DRUG

500 mg GLPG1837 as oral suspension

A single dose of 500 mg GLPG1837 administered as oral suspension

DRUG

500 mg GLPG1837 as oral tablet

A single dose of 500 mg GLPG1837 administered as oral tablet

Trial Locations (1)

Unknown

SGS LSS Clinical Pharmacology Unit Antwerp, Antwerp

Sponsors

Lead Sponsor

Galapagos NV
All Listed Sponsors
lead

Galapagos NV

INDUSTRY